EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial

Sanjay Rajagopalan iD, Mirela Dobre iD, Jean-Eudes Dazard iD, Armando Vergara-Martel, Kim Connelly, Michael E Farkouh, Juan Gaztanaga, Heather Conger, Ann Dever iD, Laleh Razavi-Nematollahi, Anas Fares, Gabriel Pereira iD und 7 weitere

Circulation · 2024

DOI: 10.1161/circulationaha.123.067620 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2024. Verfasst von Sanjay Rajagopalan und 18 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals (S.R., M.D., J.-E.D., A.V.-M., H.C., A.D., L.R.-N., A.F., G.P.), Cleveland, OH. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Diabetes Mellitus, Type 2, Fibrosis, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Persistent mineralocorticoid receptor activation is a pathologic response in type 2 diabetes and chronic kidney disease. Whereas mineralocorticoid receptor antagonists are beneficial in reducing cardiovascular complications, direct mechanistic pathways for these effects in humans are lacking. METHODS: The MAGMA trial (Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis) was a randomized, double-blind, placebo-controlled trial in patients with high-risk type 2 diabetes with chronic kidney disease (not receiving dialysis) on maximum tolerated renin-angiotensin system blockade. The primary end point was change in thoracic aortic wall volume, expressed as absolute or percent value (ΔTWV or ΔPWV), using 3T magnetic resonance imaging at 12 months. Secondary end points were changes in left ventricle (LV) mass; LV fibrosis, measured as a change in myocardial native T1; and 24-hour ambulatory and central aortic blood pressures. Tertiary end points included plasma proteomic changes in 7596 plasma proteins using an aptamer-based assay. RESULTS: A total of 79 patients were randomized to placebo (n=42) or 25 mg of spironolactone daily (n=37). After a modified intent-to-treat, including available baseline data of study end points, patients who completed the trial protocol were included in the final analyses. At the 12-month follow-up, the average change in PWV was 7.1±10.7% in the placebo group and 0.87±10.0% in the spironolactone group ( P =0.028), and ΔTWV was 1.2±1.7 cm 3 in the placebo group and 0.037±1.9 cm 3 in the spironolactone group ( P =0.022). Change in LV mass was 3.1±8.4 g in the placebo group and −5.8±8.4 g in the spironolactone group ( P =0.001). Changes in LV T1 values were significantly different between the placebo and spironolactone groups (26.0±41.9 ms in the placebo group versus a decrease of −10.1±36.3 ms in the spironolactone group; P =6.33×10 −4 ). Mediation analysis revealed that the spironolactone effect on thoracic aortic wall volume and myocardial mass remained significant after adjustment for ambulatory and central blood pressures. Proteomic analysis revealed a dominant effect of spironolactone on pathways involving oxidative stress, inflammation, and leukocyte activation. CONCLUSIONS: Among patients with diabetes with moderate to severe chronic kidney disease at elevated cardiovascular risk, treatment with spironolactone prevented progression of aortic wall volume and resulted in regression of LV mass and favorable alterations in native T1, suggesting amelioration of left-ventricular fibrosis. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02169089.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsDiabetes Mellitus, Type 2FibrosisRenal Insufficiency, ChronicSpironolactoneHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedDisease ProgressionHeart VentriclesTreatment Outcome

Stichwörter der Autor:innen

atherosclerosisdiabetes mellitus, type 2mineralocorticoid receptor antagonistsrenal insufficiency, chronic

Substanzen

Mineralocorticoid Receptor AntagonistsSpironolactone

Autor:innen und Institutionen

  • University Hospitals (S.R., M.D., J.-E.D., A.V.-M., H.C., A.D., L.R.-N., A.F., G.P.), Cleveland, OH.
  • Case Western Reserve University (S.R., M.D., J.-E.D., A.V.-M., L.R.-N., J.E.-G., M.C., C.C.), Cleveland, OH.
  • St Michael's Hospital, University of Toronto, Canada (K.C.).
  • Cedars-Sinai Health System, Los Angeles, CA (M.E.F.).
  • New York University Langone Health School of Medicine, Winthrop, Mineola (J.G.).
  • Debakey Heart and Vascular Center Houston Methodist Hospital, TX (S.A.-K.).

ORCID-Profile: Sanjay Rajagopalan, Mirela Dobre, Jean-Eudes Dazard, Ann Dever, Gabriel Pereira, Jonnelle Edwards-Glenn, Mark Cameron, Sadeer Al-Kindi, Robert D Brook, Bertram Pitt, Matthew Weir

Förderung

  • NIEHS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Rajagopalan, S., Dobre, M., Dazard, J. E., Vergara-Martel, A., Connelly, K., Farkouh, M. E., Gaztanaga, J., Conger, H., Dever, A., Razavi-Nematollahi, L., Fares, A., Pereira, G., Edwards-Glenn, J., Cameron, M., Cameron, C., Al-Kindi, S., Brook, R. D., Pitt, B., & Weir, M. (2024). Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial. Circulation. https://doi.org/10.1161/circulationaha.123.067620

Vancouver

Rajagopalan S, Dobre M, Dazard JE, Vergara-Martel A, Connelly K, Farkouh ME, et al. Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial. Circulation. 2024. doi:10.1161/circulationaha.123.067620

BibTeX
@article{Rajagopalan2024,
  author = {Rajagopalan, Sanjay and Dobre, Mirela and Dazard, Jean-Eudes and Vergara-Martel, Armando and Connelly, Kim and Farkouh, Michael E and Gaztanaga, Juan and Conger, Heather and Dever, Ann and Razavi-Nematollahi, Laleh and Fares, Anas and Pereira, Gabriel and Edwards-Glenn, Jonnelle and Cameron, Mark and Cameron, Cheryl and Al-Kindi, Sadeer and Brook, Robert D and Pitt, Bertram and Weir, Matthew},
  title = {Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial},
  journal = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.123.067620}
}
Kostenlos starten →